nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—GNRHR—Peptide GPCRs—CX3CR1—atherosclerosis	0.00853	0.0406	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—HRH1—atherosclerosis	0.00657	0.0313	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—CCR2—atherosclerosis	0.00616	0.0294	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—EDNRA—atherosclerosis	0.00616	0.0294	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRH1—atherosclerosis	0.00588	0.028	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—AGTR1—atherosclerosis	0.00524	0.025	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—EDNRA—atherosclerosis	0.00522	0.0249	CbGpPWpGaD
Degarelix—Blood alkaline phosphatase increased—Simvastatin—atherosclerosis	0.00506	0.00641	CcSEcCtD
Degarelix—Diabetes mellitus—Simvastatin—atherosclerosis	0.00506	0.00641	CcSEcCtD
Degarelix—Breast disorder—Rosuvastatin—atherosclerosis	0.00502	0.00635	CcSEcCtD
Degarelix—Swelling—Simvastatin—atherosclerosis	0.00499	0.00632	CcSEcCtD
Degarelix—Hot flush—Ezetimibe—atherosclerosis	0.00494	0.00625	CcSEcCtD
Degarelix—Gynaecomastia—Pravastatin—atherosclerosis	0.00491	0.00621	CcSEcCtD
Degarelix—Muscular weakness—Rosuvastatin—atherosclerosis	0.0049	0.0062	CcSEcCtD
Degarelix—Menopausal symptoms—Ezetimibe—atherosclerosis	0.00489	0.00619	CcSEcCtD
Degarelix—Diabetes mellitus—Niacin—atherosclerosis	0.00465	0.00588	CcSEcCtD
Degarelix—Atrial fibrillation—Simvastatin—atherosclerosis	0.00465	0.00588	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Pravastatin—atherosclerosis	0.00458	0.00579	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00435	0.0208	CbGpPWpGaD
Degarelix—Depression—Rosuvastatin—atherosclerosis	0.00427	0.0054	CcSEcCtD
Degarelix—Atrial fibrillation—Niacin—atherosclerosis	0.00427	0.0054	CcSEcCtD
Degarelix—Hot flush—Pravastatin—atherosclerosis	0.00426	0.00539	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—UTS2—atherosclerosis	0.00424	0.0202	CbGpPWpGaD
Degarelix—Menopausal symptoms—Pravastatin—atherosclerosis	0.00422	0.00534	CcSEcCtD
Degarelix—Breast disorder—Ezetimibe—atherosclerosis	0.00417	0.00528	CcSEcCtD
Degarelix—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00416	0.00527	CcSEcCtD
Degarelix—Muscular weakness—Ezetimibe—atherosclerosis	0.00407	0.00515	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—CASR—atherosclerosis	0.00406	0.0194	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00405	0.00512	CcSEcCtD
Degarelix—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00401	0.00508	CcSEcCtD
Degarelix—Abdominal discomfort—Lovastatin—atherosclerosis	0.0039	0.00494	CcSEcCtD
Degarelix—Muscular weakness—Simvastatin—atherosclerosis	0.00388	0.00492	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—UTS2—atherosclerosis	0.00379	0.0181	CbGpPWpGaD
Degarelix—Erectile dysfunction—Lovastatin—atherosclerosis	0.00375	0.00474	CcSEcCtD
Degarelix—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00368	0.00465	CcSEcCtD
Degarelix—Abdominal discomfort—Simvastatin—atherosclerosis	0.00365	0.00462	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CASR—atherosclerosis	0.00363	0.0173	CbGpPWpGaD
Degarelix—Muscular weakness—Niacin—atherosclerosis	0.00357	0.00451	CcSEcCtD
Degarelix—Urinary tract infection—Lovastatin—atherosclerosis	0.00353	0.00446	CcSEcCtD
Degarelix—Muscular weakness—Pravastatin—atherosclerosis	0.00351	0.00444	CcSEcCtD
Degarelix—Erectile dysfunction—Simvastatin—atherosclerosis	0.00351	0.00444	CcSEcCtD
Degarelix—Arrhythmia—Rosuvastatin—atherosclerosis	0.00343	0.00435	CcSEcCtD
Degarelix—Depression—Simvastatin—atherosclerosis	0.00338	0.00428	CcSEcCtD
Degarelix—Mental disorder—Rosuvastatin—atherosclerosis	0.00337	0.00426	CcSEcCtD
Degarelix—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00337	0.00426	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—HRH1—atherosclerosis	0.00332	0.0158	CbGpPWpGaD
Degarelix—Erectile dysfunction—Niacin—atherosclerosis	0.00322	0.00407	CcSEcCtD
Degarelix—Dysuria—Pravastatin—atherosclerosis	0.00322	0.00407	CcSEcCtD
Degarelix—Erectile dysfunction—Pravastatin—atherosclerosis	0.00317	0.00401	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00315	0.015	CbGpPWpGaD
Degarelix—Oedema peripheral—Ezetimibe—atherosclerosis	0.00315	0.00398	CcSEcCtD
Degarelix—Weight increased—Pravastatin—atherosclerosis	0.00313	0.00396	CcSEcCtD
Degarelix—Weight decreased—Pravastatin—atherosclerosis	0.00311	0.00394	CcSEcCtD
Degarelix—Depression—Pravastatin—atherosclerosis	0.00306	0.00387	CcSEcCtD
Degarelix—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00302	0.00383	CcSEcCtD
Degarelix—Myocardial infarction—Pravastatin—atherosclerosis	0.00301	0.00381	CcSEcCtD
Degarelix—Urinary tract infection—Pravastatin—atherosclerosis	0.00298	0.00377	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—EDNRA—atherosclerosis	0.00294	0.014	CbGpPWpGaD
Degarelix—Chills—Lovastatin—atherosclerosis	0.00292	0.0037	CcSEcCtD
Degarelix—Angiopathy—Ezetimibe—atherosclerosis	0.0029	0.00367	CcSEcCtD
Degarelix—Immune system disorder—Ezetimibe—atherosclerosis	0.00289	0.00365	CcSEcCtD
Degarelix—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00288	0.00364	CcSEcCtD
Degarelix—Alopecia—Lovastatin—atherosclerosis	0.00288	0.00364	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—GHRL—atherosclerosis	0.00286	0.0136	CbGpPWpGaD
Degarelix—Arthralgia—Rosuvastatin—atherosclerosis	0.00285	0.0036	CcSEcCtD
Degarelix—Alopecia—Ezetimibe—atherosclerosis	0.00282	0.00357	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.00281	0.0134	CbGpPWpGaD
Degarelix—Mental disorder—Ezetimibe—atherosclerosis	0.0028	0.00354	CcSEcCtD
Degarelix—Hypoaesthesia—Niacin—atherosclerosis	0.00278	0.00352	CcSEcCtD
Degarelix—Malnutrition—Ezetimibe—atherosclerosis	0.00278	0.00352	CcSEcCtD
Degarelix—Erythema—Ezetimibe—atherosclerosis	0.00278	0.00352	CcSEcCtD
Degarelix—Oedema peripheral—Niacin—atherosclerosis	0.00276	0.00349	CcSEcCtD
Degarelix—Back pain—Lovastatin—atherosclerosis	0.00274	0.00347	CcSEcCtD
Degarelix—Hypoaesthesia—Pravastatin—atherosclerosis	0.00274	0.00347	CcSEcCtD
Degarelix—Chills—Simvastatin—atherosclerosis	0.00273	0.00346	CcSEcCtD
Degarelix—Muscle spasms—Lovastatin—atherosclerosis	0.00273	0.00345	CcSEcCtD
Degarelix—Alopecia—Simvastatin—atherosclerosis	0.00269	0.00341	CcSEcCtD
Degarelix—Back pain—Ezetimibe—atherosclerosis	0.00269	0.0034	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.00269	0.0128	CbGpPWpGaD
Degarelix—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00268	0.00339	CcSEcCtD
Degarelix—Muscle spasms—Ezetimibe—atherosclerosis	0.00267	0.00338	CcSEcCtD
Degarelix—Vision blurred—Lovastatin—atherosclerosis	0.00267	0.00338	CcSEcCtD
Degarelix—Mental disorder—Simvastatin—atherosclerosis	0.00267	0.00338	CcSEcCtD
Degarelix—Erythema—Simvastatin—atherosclerosis	0.00265	0.00336	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00264	0.0126	CbGpPWpGaD
Degarelix—Ill-defined disorder—Lovastatin—atherosclerosis	0.00263	0.00333	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—atherosclerosis	0.00263	0.0125	CbGpPWpGaD
Degarelix—Eye disorder—Niacin—atherosclerosis	0.00261	0.00331	CcSEcCtD
Degarelix—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00258	0.00327	CcSEcCtD
Degarelix—Anaemia—Ezetimibe—atherosclerosis	0.00257	0.00325	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—atherosclerosis	0.00256	0.0122	CbGpPWpGaD
Degarelix—Malaise—Lovastatin—atherosclerosis	0.00256	0.00324	CcSEcCtD
Degarelix—Cardiac disorder—Pravastatin—atherosclerosis	0.00256	0.00324	CcSEcCtD
Degarelix—Muscle spasms—Simvastatin—atherosclerosis	0.00255	0.00323	CcSEcCtD
Degarelix—Angiopathy—Niacin—atherosclerosis	0.00254	0.00321	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—KNG1—atherosclerosis	0.00251	0.012	CbGpPWpGaD
Degarelix—Chills—Niacin—atherosclerosis	0.00251	0.00318	CcSEcCtD
Degarelix—Malaise—Ezetimibe—atherosclerosis	0.00251	0.00317	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.0025	0.0119	CbGpPWpGaD
Degarelix—Vision blurred—Simvastatin—atherosclerosis	0.0025	0.00316	CcSEcCtD
Degarelix—Arrhythmia—Niacin—atherosclerosis	0.0025	0.00316	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—AGTR1—atherosclerosis	0.0025	0.0119	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00249	0.00315	CcSEcCtD
Degarelix—Alopecia—Niacin—atherosclerosis	0.00247	0.00313	CcSEcCtD
Degarelix—Chills—Pravastatin—atherosclerosis	0.00247	0.00313	CcSEcCtD
Degarelix—Insomnia—Rosuvastatin—atherosclerosis	0.00247	0.00313	CcSEcCtD
Degarelix—Ill-defined disorder—Simvastatin—atherosclerosis	0.00246	0.00311	CcSEcCtD
Degarelix—Arrhythmia—Pravastatin—atherosclerosis	0.00246	0.00311	CcSEcCtD
Degarelix—Palpitations—Ezetimibe—atherosclerosis	0.00246	0.00311	CcSEcCtD
Degarelix—Anaemia—Simvastatin—atherosclerosis	0.00245	0.0031	CcSEcCtD
Degarelix—Malnutrition—Niacin—atherosclerosis	0.00244	0.00308	CcSEcCtD
Degarelix—Erythema—Niacin—atherosclerosis	0.00244	0.00308	CcSEcCtD
Degarelix—Alopecia—Pravastatin—atherosclerosis	0.00243	0.00308	CcSEcCtD
Degarelix—Arthralgia—Lovastatin—atherosclerosis	0.00241	0.00306	CcSEcCtD
Degarelix—Hypertension—Ezetimibe—atherosclerosis	0.0024	0.00304	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CCL4—atherosclerosis	0.0024	0.0114	CbGpPWpGaD
Degarelix—Malaise—Simvastatin—atherosclerosis	0.00239	0.00303	CcSEcCtD
Degarelix—Discomfort—Lovastatin—atherosclerosis	0.00239	0.00302	CcSEcCtD
Degarelix—Arthralgia—Ezetimibe—atherosclerosis	0.00237	0.003	CcSEcCtD
Degarelix—Dry mouth—Lovastatin—atherosclerosis	0.00236	0.00299	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00235	0.00298	CcSEcCtD
Degarelix—Muscle spasms—Niacin—atherosclerosis	0.00234	0.00296	CcSEcCtD
Degarelix—Discomfort—Ezetimibe—atherosclerosis	0.00234	0.00296	CcSEcCtD
Degarelix—Pain—Rosuvastatin—atherosclerosis	0.00234	0.00296	CcSEcCtD
Degarelix—Constipation—Rosuvastatin—atherosclerosis	0.00234	0.00296	CcSEcCtD
Degarelix—Dry mouth—Ezetimibe—atherosclerosis	0.00232	0.00293	CcSEcCtD
Degarelix—Anaphylactic shock—Lovastatin—atherosclerosis	0.00231	0.00293	CcSEcCtD
Degarelix—Muscle spasms—Pravastatin—atherosclerosis	0.00231	0.00292	CcSEcCtD
Degarelix—Vision blurred—Niacin—atherosclerosis	0.0023	0.0029	CcSEcCtD
Degarelix—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00227	0.00287	CcSEcCtD
Degarelix—Vision blurred—Pravastatin—atherosclerosis	0.00226	0.00286	CcSEcCtD
Degarelix—Arthralgia—Simvastatin—atherosclerosis	0.00226	0.00286	CcSEcCtD
Degarelix—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00225	0.00285	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	0.00225	0.0107	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00223	0.00283	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—atherosclerosis	0.00223	0.0106	CbGpPWpGaD
Degarelix—Discomfort—Simvastatin—atherosclerosis	0.00223	0.00282	CcSEcCtD
Degarelix—Nervous system disorder—Ezetimibe—atherosclerosis	0.00223	0.00282	CcSEcCtD
Degarelix—Ill-defined disorder—Pravastatin—atherosclerosis	0.00222	0.00282	CcSEcCtD
Degarelix—Anaemia—Pravastatin—atherosclerosis	0.00222	0.0028	CcSEcCtD
Degarelix—Skin disorder—Ezetimibe—atherosclerosis	0.0022	0.00279	CcSEcCtD
Degarelix—Urticaria—Rosuvastatin—atherosclerosis	0.00217	0.00275	CcSEcCtD
Degarelix—Anaphylactic shock—Simvastatin—atherosclerosis	0.00216	0.00274	CcSEcCtD
Degarelix—Malaise—Pravastatin—atherosclerosis	0.00216	0.00274	CcSEcCtD
Degarelix—Abdominal pain—Rosuvastatin—atherosclerosis	0.00216	0.00273	CcSEcCtD
Degarelix—Palpitations—Niacin—atherosclerosis	0.00215	0.00272	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00215	0.0102	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—UTS2—atherosclerosis	0.00214	0.0102	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—EDN1—atherosclerosis	0.00212	0.0101	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00211	0.00267	CcSEcCtD
Degarelix—Insomnia—Lovastatin—atherosclerosis	0.00209	0.00265	CcSEcCtD
Degarelix—Arthralgia—Niacin—atherosclerosis	0.00207	0.00262	CcSEcCtD
Degarelix—Hypertension—Pravastatin—atherosclerosis	0.00207	0.00262	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00207	0.00262	CcSEcCtD
Degarelix—Dyspnoea—Lovastatin—atherosclerosis	0.00206	0.00261	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00206	0.00261	CcSEcCtD
Degarelix—Insomnia—Ezetimibe—atherosclerosis	0.00205	0.0026	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CX3CR1—atherosclerosis	0.00205	0.00976	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CASR—atherosclerosis	0.00205	0.00976	CbGpPWpGaD
Degarelix—Arthralgia—Pravastatin—atherosclerosis	0.00204	0.00258	CcSEcCtD
Degarelix—Dry mouth—Niacin—atherosclerosis	0.00203	0.00257	CcSEcCtD
Degarelix—Dyspnoea—Ezetimibe—atherosclerosis	0.00202	0.00256	CcSEcCtD
Degarelix—Discomfort—Pravastatin—atherosclerosis	0.00202	0.00255	CcSEcCtD
Degarelix—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00201	0.00255	CcSEcCtD
Degarelix—Decreased appetite—Lovastatin—atherosclerosis	0.00201	0.00255	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CX3CL1—atherosclerosis	0.00201	0.00957	CbGpPWpGaD
Degarelix—Fatigue—Lovastatin—atherosclerosis	0.002	0.00252	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.00199	0.00949	CbGpPWpGaD
Degarelix—Anaphylactic shock—Niacin—atherosclerosis	0.00199	0.00252	CcSEcCtD
Degarelix—Pain—Lovastatin—atherosclerosis	0.00198	0.0025	CcSEcCtD
Degarelix—Constipation—Lovastatin—atherosclerosis	0.00198	0.0025	CcSEcCtD
Degarelix—Decreased appetite—Ezetimibe—atherosclerosis	0.00197	0.0025	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00197	0.0025	CcSEcCtD
Degarelix—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00196	0.00248	CcSEcCtD
Degarelix—Asthenia—Rosuvastatin—atherosclerosis	0.00196	0.00248	CcSEcCtD
Degarelix—Insomnia—Simvastatin—atherosclerosis	0.00196	0.00248	CcSEcCtD
Degarelix—Anaphylactic shock—Pravastatin—atherosclerosis	0.00196	0.00248	CcSEcCtD
Degarelix—Fatigue—Ezetimibe—atherosclerosis	0.00196	0.00248	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.00194	0.00927	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.00194	0.00927	CbGpPWpGaD
Degarelix—Constipation—Ezetimibe—atherosclerosis	0.00194	0.00246	CcSEcCtD
Degarelix—Pain—Ezetimibe—atherosclerosis	0.00194	0.00246	CcSEcCtD
Degarelix—Pruritus—Rosuvastatin—atherosclerosis	0.00193	0.00244	CcSEcCtD
Degarelix—Skin disorder—Niacin—atherosclerosis	0.00193	0.00244	CcSEcCtD
Degarelix—Dyspnoea—Simvastatin—atherosclerosis	0.00193	0.00244	CcSEcCtD
Degarelix—Hyperhidrosis—Niacin—atherosclerosis	0.00192	0.00243	CcSEcCtD
Degarelix—Feeling abnormal—Lovastatin—atherosclerosis	0.00191	0.00241	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CNR2—atherosclerosis	0.0019	0.00908	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.0019	0.00903	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.00189	0.00902	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00189	0.00239	CcSEcCtD
Degarelix—Hyperhidrosis—Pravastatin—atherosclerosis	0.00189	0.00239	CcSEcCtD
Degarelix—Decreased appetite—Simvastatin—atherosclerosis	0.00188	0.00238	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—HRH1—atherosclerosis	0.00187	0.00893	CbGpPWpGaD
Degarelix—Feeling abnormal—Ezetimibe—atherosclerosis	0.00187	0.00237	CcSEcCtD
Degarelix—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00187	0.00236	CcSEcCtD
Degarelix—Diarrhoea—Rosuvastatin—atherosclerosis	0.00187	0.00236	CcSEcCtD
Degarelix—Fatigue—Simvastatin—atherosclerosis	0.00187	0.00236	CcSEcCtD
Degarelix—Hypotension—Niacin—atherosclerosis	0.00186	0.00235	CcSEcCtD
Degarelix—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00186	0.00235	CcSEcCtD
Degarelix—Constipation—Simvastatin—atherosclerosis	0.00185	0.00234	CcSEcCtD
Degarelix—Pain—Simvastatin—atherosclerosis	0.00185	0.00234	CcSEcCtD
Degarelix—Urticaria—Lovastatin—atherosclerosis	0.00184	0.00233	CcSEcCtD
Degarelix—Abdominal pain—Lovastatin—atherosclerosis	0.00183	0.00232	CcSEcCtD
Degarelix—Body temperature increased—Lovastatin—atherosclerosis	0.00183	0.00232	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00181	0.00229	CcSEcCtD
Degarelix—Dizziness—Rosuvastatin—atherosclerosis	0.00181	0.00229	CcSEcCtD
Degarelix—Urticaria—Ezetimibe—atherosclerosis	0.0018	0.00228	CcSEcCtD
Degarelix—Insomnia—Niacin—atherosclerosis	0.0018	0.00228	CcSEcCtD
Degarelix—Body temperature increased—Ezetimibe—atherosclerosis	0.00179	0.00227	CcSEcCtD
Degarelix—Abdominal pain—Ezetimibe—atherosclerosis	0.00179	0.00227	CcSEcCtD
Degarelix—Feeling abnormal—Simvastatin—atherosclerosis	0.00178	0.00226	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00178	0.00226	CcSEcCtD
Degarelix—Dyspnoea—Niacin—atherosclerosis	0.00177	0.00224	CcSEcCtD
Degarelix—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00177	0.00224	CcSEcCtD
Degarelix—Insomnia—Pravastatin—atherosclerosis	0.00177	0.00224	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—AGT—atherosclerosis	0.00176	0.00837	CbGpPWpGaD
Degarelix—Dyspnoea—Pravastatin—atherosclerosis	0.00174	0.00221	CcSEcCtD
Degarelix—Decreased appetite—Niacin—atherosclerosis	0.00173	0.00219	CcSEcCtD
Degarelix—Rash—Rosuvastatin—atherosclerosis	0.00172	0.00218	CcSEcCtD
Degarelix—Dermatitis—Rosuvastatin—atherosclerosis	0.00172	0.00218	CcSEcCtD
Degarelix—Urticaria—Simvastatin—atherosclerosis	0.00172	0.00218	CcSEcCtD
Degarelix—Gastrointestinal disorder—Niacin—atherosclerosis	0.00172	0.00217	CcSEcCtD
Degarelix—Body temperature increased—Simvastatin—atherosclerosis	0.00171	0.00217	CcSEcCtD
Degarelix—Abdominal pain—Simvastatin—atherosclerosis	0.00171	0.00217	CcSEcCtD
Degarelix—Headache—Rosuvastatin—atherosclerosis	0.00171	0.00216	CcSEcCtD
Degarelix—Hypersensitivity—Lovastatin—atherosclerosis	0.00171	0.00216	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—HRH1—atherosclerosis	0.0017	0.00811	CbGpPWpGaD
Degarelix—Decreased appetite—Pravastatin—atherosclerosis	0.0017	0.00215	CcSEcCtD
Degarelix—Pain—Niacin—atherosclerosis	0.0017	0.00215	CcSEcCtD
Degarelix—Fatigue—Pravastatin—atherosclerosis	0.00169	0.00214	CcSEcCtD
Degarelix—Constipation—Pravastatin—atherosclerosis	0.00167	0.00212	CcSEcCtD
Degarelix—Pain—Pravastatin—atherosclerosis	0.00167	0.00212	CcSEcCtD
Degarelix—Hypersensitivity—Ezetimibe—atherosclerosis	0.00167	0.00212	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.00166	0.00793	CbGpPWpGaD
Degarelix—Asthenia—Lovastatin—atherosclerosis	0.00166	0.0021	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.00165	0.00788	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL3—atherosclerosis	0.00164	0.0078	CbGpPWpGaD
Degarelix—Pruritus—Lovastatin—atherosclerosis	0.00164	0.00207	CcSEcCtD
Degarelix—Asthenia—Ezetimibe—atherosclerosis	0.00163	0.00206	CcSEcCtD
Degarelix—Gastrointestinal pain—Niacin—atherosclerosis	0.00163	0.00206	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—F2—atherosclerosis	0.00162	0.00774	CbGpPWpGaD
Degarelix—Nausea—Rosuvastatin—atherosclerosis	0.00162	0.00205	CcSEcCtD
Degarelix—Feeling abnormal—Pravastatin—atherosclerosis	0.00161	0.00204	CcSEcCtD
Degarelix—Pruritus—Ezetimibe—atherosclerosis	0.00161	0.00203	CcSEcCtD
Degarelix—Gastrointestinal pain—Pravastatin—atherosclerosis	0.0016	0.00203	CcSEcCtD
Degarelix—Hypersensitivity—Simvastatin—atherosclerosis	0.00159	0.00202	CcSEcCtD
Degarelix—Diarrhoea—Lovastatin—atherosclerosis	0.00158	0.002	CcSEcCtD
Degarelix—Urticaria—Niacin—atherosclerosis	0.00158	0.002	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.00157	0.00749	CbGpPWpGaD
Degarelix—Abdominal pain—Niacin—atherosclerosis	0.00157	0.00199	CcSEcCtD
Degarelix—Body temperature increased—Niacin—atherosclerosis	0.00157	0.00199	CcSEcCtD
Degarelix—Urticaria—Pravastatin—atherosclerosis	0.00155	0.00197	CcSEcCtD
Degarelix—Asthenia—Simvastatin—atherosclerosis	0.00155	0.00197	CcSEcCtD
Degarelix—Diarrhoea—Ezetimibe—atherosclerosis	0.00155	0.00197	CcSEcCtD
Degarelix—Abdominal pain—Pravastatin—atherosclerosis	0.00155	0.00196	CcSEcCtD
Degarelix—Body temperature increased—Pravastatin—atherosclerosis	0.00155	0.00196	CcSEcCtD
Degarelix—Pruritus—Simvastatin—atherosclerosis	0.00153	0.00194	CcSEcCtD
Degarelix—Dizziness—Lovastatin—atherosclerosis	0.00153	0.00194	CcSEcCtD
Degarelix—Dizziness—Ezetimibe—atherosclerosis	0.0015	0.0019	CcSEcCtD
Degarelix—Diarrhoea—Simvastatin—atherosclerosis	0.00148	0.00187	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—EDNRA—atherosclerosis	0.00148	0.00706	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCR2—atherosclerosis	0.00148	0.00706	CbGpPWpGaD
Degarelix—Vomiting—Lovastatin—atherosclerosis	0.00147	0.00186	CcSEcCtD
Degarelix—Hypersensitivity—Niacin—atherosclerosis	0.00146	0.00185	CcSEcCtD
Degarelix—Rash—Lovastatin—atherosclerosis	0.00146	0.00185	CcSEcCtD
Degarelix—Dermatitis—Lovastatin—atherosclerosis	0.00146	0.00184	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.00145	0.00692	CbGpPWpGaD
Degarelix—Headache—Lovastatin—atherosclerosis	0.00145	0.00183	CcSEcCtD
Degarelix—Vomiting—Ezetimibe—atherosclerosis	0.00144	0.00183	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—GHRL—atherosclerosis	0.00144	0.00688	CbGpPWpGaD
Degarelix—Hypersensitivity—Pravastatin—atherosclerosis	0.00144	0.00182	CcSEcCtD
Degarelix—Dizziness—Simvastatin—atherosclerosis	0.00143	0.00181	CcSEcCtD
Degarelix—Rash—Ezetimibe—atherosclerosis	0.00143	0.00181	CcSEcCtD
Degarelix—Dermatitis—Ezetimibe—atherosclerosis	0.00143	0.00181	CcSEcCtD
Degarelix—Asthenia—Niacin—atherosclerosis	0.00143	0.0018	CcSEcCtD
Degarelix—Headache—Ezetimibe—atherosclerosis	0.00142	0.0018	CcSEcCtD
Degarelix—Pruritus—Niacin—atherosclerosis	0.00141	0.00178	CcSEcCtD
Degarelix—Asthenia—Pravastatin—atherosclerosis	0.0014	0.00178	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.0014	0.00668	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.00139	0.00663	CbGpPWpGaD
Degarelix—Pruritus—Pravastatin—atherosclerosis	0.00138	0.00175	CcSEcCtD
Degarelix—Vomiting—Simvastatin—atherosclerosis	0.00138	0.00174	CcSEcCtD
Degarelix—Nausea—Lovastatin—atherosclerosis	0.00137	0.00174	CcSEcCtD
Degarelix—Rash—Simvastatin—atherosclerosis	0.00136	0.00173	CcSEcCtD
Degarelix—Dermatitis—Simvastatin—atherosclerosis	0.00136	0.00173	CcSEcCtD
Degarelix—Diarrhoea—Niacin—atherosclerosis	0.00136	0.00172	CcSEcCtD
Degarelix—Headache—Simvastatin—atherosclerosis	0.00136	0.00172	CcSEcCtD
Degarelix—Nausea—Ezetimibe—atherosclerosis	0.00135	0.00171	CcSEcCtD
Degarelix—Diarrhoea—Pravastatin—atherosclerosis	0.00134	0.00169	CcSEcCtD
Degarelix—Dizziness—Niacin—atherosclerosis	0.00131	0.00166	CcSEcCtD
Degarelix—Dizziness—Pravastatin—atherosclerosis	0.00129	0.00164	CcSEcCtD
Degarelix—Nausea—Simvastatin—atherosclerosis	0.00129	0.00163	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—KNG1—atherosclerosis	0.00127	0.00604	CbGpPWpGaD
Degarelix—Vomiting—Niacin—atherosclerosis	0.00126	0.0016	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—AGTR1—atherosclerosis	0.00126	0.006	CbGpPWpGaD
Degarelix—Rash—Niacin—atherosclerosis	0.00125	0.00159	CcSEcCtD
Degarelix—Dermatitis—Niacin—atherosclerosis	0.00125	0.00158	CcSEcCtD
Degarelix—Headache—Niacin—atherosclerosis	0.00125	0.00158	CcSEcCtD
Degarelix—Vomiting—Pravastatin—atherosclerosis	0.00124	0.00157	CcSEcCtD
Degarelix—Rash—Pravastatin—atherosclerosis	0.00123	0.00156	CcSEcCtD
Degarelix—Dermatitis—Pravastatin—atherosclerosis	0.00123	0.00156	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CCL4—atherosclerosis	0.00123	0.00586	CbGpPWpGaD
Degarelix—Headache—Pravastatin—atherosclerosis	0.00123	0.00155	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—UTS2—atherosclerosis	0.00121	0.00575	CbGpPWpGaD
Degarelix—Nausea—Niacin—atherosclerosis	0.00118	0.00149	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.00116	0.00555	CbGpPWpGaD
Degarelix—Nausea—Pravastatin—atherosclerosis	0.00116	0.00147	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CASR—atherosclerosis	0.00116	0.00552	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—UTS2—atherosclerosis	0.0011	0.00523	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CNR2—atherosclerosis	0.00108	0.00513	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00108	0.00512	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—EDN1—atherosclerosis	0.00107	0.00509	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL5—atherosclerosis	0.00106	0.00505	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CX3CR1—atherosclerosis	0.00105	0.00501	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CASR—atherosclerosis	0.00105	0.00501	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CX3CL1—atherosclerosis	0.00103	0.00491	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRH1—atherosclerosis	0.00101	0.00479	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CNR2—atherosclerosis	0.000977	0.00466	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000958	0.00457	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—AGT—atherosclerosis	0.000886	0.00422	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL3—atherosclerosis	0.00084	0.00401	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCR2—atherosclerosis	0.000837	0.00399	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—EDNRA—atherosclerosis	0.000837	0.00399	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—F2—atherosclerosis	0.000819	0.0039	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GHRL—atherosclerosis	0.000816	0.00389	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOA4—atherosclerosis	0.000789	0.00376	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	0.000786	0.00375	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EDNRA—atherosclerosis	0.00076	0.00362	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCR2—atherosclerosis	0.00076	0.00362	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000758	0.00361	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GHRL—atherosclerosis	0.000741	0.00353	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL2—atherosclerosis	0.00073	0.00348	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL4—atherosclerosis	0.000727	0.00346	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—KNG1—atherosclerosis	0.000716	0.00341	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AGTR1—atherosclerosis	0.000712	0.00339	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOA2—atherosclerosis	0.000679	0.00324	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KNG1—atherosclerosis	0.00065	0.0031	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—UTS2—atherosclerosis	0.000648	0.00309	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AGTR1—atherosclerosis	0.000646	0.00308	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASR—atherosclerosis	0.000621	0.00296	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CX3CR1—atherosclerosis	0.000621	0.00296	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CX3CL1—atherosclerosis	0.000609	0.0029	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—EDN1—atherosclerosis	0.000603	0.00288	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCL5—atherosclerosis	0.000599	0.00285	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CNR2—atherosclerosis	0.000577	0.00275	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—atherosclerosis	0.000577	0.00275	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MMP3—atherosclerosis	0.000576	0.00275	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	0.000575	0.00274	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PRKCG—atherosclerosis	0.000569	0.00271	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EDN1—atherosclerosis	0.000548	0.00261	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL5—atherosclerosis	0.000544	0.00259	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PRKCG—atherosclerosis	0.000517	0.00246	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VWF—atherosclerosis	0.000515	0.00245	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOC3—atherosclerosis	0.000511	0.00244	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LDLR—atherosclerosis	0.000508	0.00242	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AGT—atherosclerosis	0.000501	0.00239	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL3—atherosclerosis	0.000496	0.00237	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NCF1—atherosclerosis	0.000475	0.00227	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—F2—atherosclerosis	0.000463	0.00221	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AGT—atherosclerosis	0.000455	0.00217	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EDNRA—atherosclerosis	0.000449	0.00214	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCR2—atherosclerosis	0.000449	0.00214	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CYBA—atherosclerosis	0.000447	0.00213	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000443	0.00211	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PLAT—atherosclerosis	0.000437	0.00209	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GHRL—atherosclerosis	0.000437	0.00209	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PARP1—atherosclerosis	0.000437	0.00209	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—F2—atherosclerosis	0.00042	0.002	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—atherosclerosis	0.000402	0.00192	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KNG1—atherosclerosis	0.000384	0.00183	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AGTR1—atherosclerosis	0.000382	0.00182	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL2—atherosclerosis	0.000374	0.00178	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PLG—atherosclerosis	0.000372	0.00177	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SOCS3—atherosclerosis	0.000352	0.00168	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP3—atherosclerosis	0.00034	0.00162	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IGF2—atherosclerosis	0.000339	0.00161	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOB—atherosclerosis	0.000329	0.00157	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—atherosclerosis	0.000326	0.00155	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EDN1—atherosclerosis	0.000324	0.00154	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL5—atherosclerosis	0.000321	0.00153	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LPL—atherosclerosis	0.000314	0.0015	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRKCG—atherosclerosis	0.000305	0.00146	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SPP1—atherosclerosis	0.000297	0.00142	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—atherosclerosis	0.000296	0.00141	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDGFB—atherosclerosis	0.000275	0.00131	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AGT—atherosclerosis	0.000269	0.00128	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOE—atherosclerosis	0.000263	0.00125	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LEP—atherosclerosis	0.000263	0.00125	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CAV1—atherosclerosis	0.000261	0.00124	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOA1—atherosclerosis	0.00026	0.00124	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ESR1—atherosclerosis	0.000251	0.0012	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—F2—atherosclerosis	0.000248	0.00118	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—atherosclerosis	0.000238	0.00113	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAPK3—atherosclerosis	0.000227	0.00108	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—INS—atherosclerosis	0.000225	0.00107	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL2—atherosclerosis	0.000221	0.00105	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IGF1—atherosclerosis	0.000217	0.00104	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SERPINE1—atherosclerosis	0.000207	0.000984	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOS3—atherosclerosis	0.000197	0.00094	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—atherosclerosis	0.000175	0.000834	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—atherosclerosis	0.000169	0.000805	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—atherosclerosis	0.000166	0.000793	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—atherosclerosis	0.000158	0.000754	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NFKB1—atherosclerosis	0.000157	0.000746	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK8—atherosclerosis	0.000154	0.000733	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—atherosclerosis	0.000153	0.000731	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—atherosclerosis	0.000142	0.000677	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—atherosclerosis	0.000141	0.00067	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK3—atherosclerosis	0.000134	0.000641	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TGFB1—atherosclerosis	0.00013	0.000621	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—atherosclerosis	9.82e-05	0.000468	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—atherosclerosis	9.06e-05	0.000432	CbGpPWpGaD
